Registry for patients with pancreatic ductal adenocarcinoma
PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma
This study is collecting information from people newly diagnosed with pancreatic cancer to help improve understanding and treatment of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Ulm Academic / other |
| Locations | 1 site (Ulm) |
| Trial ID | NCT04099134 on ClinicalTrials.gov |
What this trial studies
PaCaReg is a multicenter registry that collects data on the clinical, epidemiological, and biological characteristics of patients diagnosed with pancreatic ductal adenocarcinoma. The study aims to gather comprehensive information to better understand the disease and improve future treatment strategies. Participants must be treatment-naive and provide written informed consent to be included in the registry. The study focuses on patients with confirmed or highly suspicious diagnoses of pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with treatment-naive pancreatic ductal adenocarcinoma or a highly suspicious diagnosis.
Not a fit: Patients with papillary cancer or neuroendocrine pancreatic tumors will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of pancreatic ductal adenocarcinoma and lead to improved treatment options for patients.
How similar studies have performed: While this registry approach is common, the specific focus on pancreatic ductal adenocarcinoma may provide novel insights that have not been extensively explored in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended resection) * Age =\>18 years * written informed consent Exclusion Criteria: * papillary cancer * neuroendocrine pancreatic tumors
Where this trial is running
Ulm
- Universitätsklinikum Ulm — Ulm, Germany (Recruiting)
Study contacts
- Principal investigator: Thomas Seufferlein, MD — Ulm University Hospital
- Study coordinator: Thomas Seufferlein, MD
- Email: thomas.seufferlein@uniklinik-ulm.de
- Phone: +49 731 50044501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.